<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12275">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501592</url>
  </required_header>
  <id_info>
    <org_study_id>747-203</org_study_id>
    <nct_id>NCT00501592</nct_id>
  </id_info>
  <brief_title>Study of INT-747 in Patients With Diabetes and Presumed NAFLD</brief_title>
  <official_title>An Exploratory Study of INT-747 in Patients With Type 2 Diabetes Mellitus and Presumed Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to assess, in patients with Type 2 diabetes
      mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following:

        -  The safety and tolerability of multiple doses of INT 747;

        -  The effects of 2 dose levels (25 mg and 50 mg) of INT 747 on insulin resistance and
           glucose homeostasis;

        -  Effects of INT-747 on hepatocellular function as measured by assessment of liver
           enzymes and biochemical markers of hepatic and metabolic function and inflammation,
           and;

        -  Trough concentrations of INT-747 and its metabolites, glyco 6-ethyl chenodeoxycholic
           acid (6-EDCA) and tauro 6-ECDCA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, double-blind, randomized, placebo-controlled, multiple-dose,
      parallel-group study. Three (3) cohorts of 12 patients each will receive either placebo, 25
      mg INT-747, or 50 mg INT-747 by mouth daily for 6 weeks.

      The primary objective of assessing changes in insulin resistance and glucose homeostasis
      will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the
      end of 6 weeks of treatment (Day 43). Other endpoints will be evaluated by monitoring
      adverse experiences; vital signs; clinical laboratory values; plasma drug and metabolite
      concentrations; and general health and well-being.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Insulin Resistance and Glucose Homeostasis</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular Function</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hepatocellular function as measured by assessment of liver enzymes and biochemical markers of hepatic and metabolic function</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>25 mg INT-747</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg INT-747</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INT-747</intervention_name>
    <description>25 mg by mouth once daily, 50 mg by mouth once daily</description>
    <arm_group_label>25 mg INT-747</arm_group_label>
    <arm_group_label>50 mg INT-747</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes, defined by the American Diabetes Association (ADA), as one of the
             following criteria:

          -  Symptoms of diabetes plus casual plasma glucose concentration &gt;200 mg/dL (11.1
             mmol/L) or

          -  Fasting plasma glucose &gt;126 mg/dL (7.0 mmol/L) or

          -  2-hour post-load glucose &gt;200 mg/dL (11.1 mmol/L) during a 75 g oral glucose
             tolerance test (GTT).

          -  Presumed NAFLD, defined by one of the following criteria:

          -  Alanine aminotransferase (ALT) ≥47 U/L for females and ≥56 U/L for males

          -  Aspartate aminotransferase (AST) ≥47 U/L for females and ≥60 U/L for males

          -  Enlarged liver (demonstrated by ultrasound or other imaging technique)

          -  Diagnostic histological findings shown on prior biopsy (in the last 5 years).

        Exclusion Criteria:

          -  Bilirubin &gt;2 × ULN

          -  ALT &gt;155 U/L for females and &gt;185 U/L for males.

          -  AST &gt;155 U/L for females and &gt;200 U/L for males.

          -  Patients taking any antidiabetic medications, with the exception of metformin and
             sulfonylureas. If the HbA1c is &lt;11%, patients may be enrolled who have been withdrawn
             from all other diabetic medications as specified in the protocol, at the discretion
             of the Principal Investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Shapiro, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Intercept Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego VAMC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Research Associates, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwelath University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 17, 2012</lastchanged_date>
  <firstreceived_date>July 13, 2007</firstreceived_date>
  <firstreceived_results_date>June 7, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Farnesoid X receptor agonist</keyword>
  <keyword>Metabolic Disorder</keyword>
  <keyword>Diabetes</keyword>
  <keyword>NAFLD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty four subjects were enrolled in the study at 4 sites. Of the randomized subjects, 20 were randomized to INT-747 25 mg, 21 subjects to INT-747 50 mg, and 23 subjects to placebo. Study enrollment by center ranged from 4 to 31 subjects.</recruitment_details>
      <pre_assignment_details>A protocol amendment allowed for the enrollment of 14 replacement subjects (to enroll up to 56 subjects meeting eligibility requirements). The amendment pre-specified that the original 14 subjects being replaced would not be included in the efficacy analysis since they did not meet the protocol requirements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>25 mg INT-747</title>
          <description>Once daily by mouth</description>
        </group>
        <group group_id="P2">
          <title>50 mg INT-747</title>
          <description>Once daily by mouth</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Once daily by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>25 mg INT-747</title>
          <description>Once daily by mouth</description>
        </group>
        <group group_id="B2">
          <title>50 mg INT-747</title>
          <description>Once daily by mouth</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Once daily by mouth</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="23"/>
                <measurement group_id="B4" value="64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="59"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52.7" spread="8.7"/>
                <measurement group_id="B2" value="50.5" spread="10.8"/>
                <measurement group_id="B3" value="53.1" spread="12.1"/>
                <measurement group_id="B4" value="52.1" spread="10.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="23"/>
                <measurement group_id="B4" value="64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Resistance and Glucose Homeostasis</title>
        <description>The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43).</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>25 mg INT-747</title>
            <description>Once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>50 mg INT-747</title>
            <description>Once daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Once daily by mouth</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Insulin Resistance and Glucose Homeostasis</title>
            <description>The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43).</description>
            <units>mg/kg/min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Low Dose Insulin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value=".69" spread="1.12"/>
                  <measurement group_id="O2" value=".24" spread="1.62"/>
                  <measurement group_id="O3" value="-0.51" spread="1.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>High Dose Insulin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value=".73" spread="1.53"/>
                  <measurement group_id="O2" value=".42" spread="1.42"/>
                  <measurement group_id="O3" value="-0.61" spread="1.88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary endpoints are calculated as the change (post minus pre treatment) during low dose and high dose insulin infusion periods. These are compared between placebo and INT‐747 25 mg using t‐tests for independent samples. These tests will be made without correction for multiple comparisons using 0.05 as the alpha criterion for significance. Results will be described with the corresponding means and standard deviations.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.040</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary endpoints are calculated as the change (post minus pre treatment) during low dose and high dose insulin infusion periods. These are compared between placebo and INT‐747 50 mg using t‐tests for independent samples. These tests will be made without correction for multiple comparisons using 0.05 as the alpha criterion for significance. Results will be described with the corresponding means and standard deviations.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.28</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatocellular Function</title>
        <description>Hepatocellular function as measured by assessment of liver enzymes and biochemical markers of hepatic and metabolic function</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>25 mg INT-747</title>
            <description>Once daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>50 mg INT-747</title>
            <description>Once daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Once daily by mouth</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hepatocellular Function</title>
            <description>Hepatocellular function as measured by assessment of liver enzymes and biochemical markers of hepatic and metabolic function</description>
            <units>U/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>ALT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9" spread="14"/>
                  <measurement group_id="O2" value="9" spread="47"/>
                  <measurement group_id="O3" value="11" spread="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3" spread="7"/>
                  <measurement group_id="O2" value="4" spread="24"/>
                  <measurement group_id="O3" value="4" spread="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GGT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-39" spread="77"/>
                  <measurement group_id="O2" value="-23" spread="56"/>
                  <measurement group_id="O3" value="5" spread="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0031</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year, 7 monhts</time_frame>
      <group_list>
        <group group_id="E1">
          <title>25 mg INT-747</title>
          <description>Once daily by mouth</description>
        </group>
        <group group_id="E2">
          <title>50 mg INT-747</title>
          <description>Once daily by mouth</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Once daily by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel Puncture Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash maculopapular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All proposed publications based on this study shall be approved by the Sponsor prior to submission for publication. Such approval will not be unreasonably witheld. Publications will reflect the contributions made by the Investigators, Sponsor personnel and other groups involved in the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cathi Sciacca, Sr. Director, Clinical Operations</name_or_title>
      <organization>Intercept Pharmaceuticals, Inc.</organization>
      <phone>858-652-6800</phone>
      <email>csciacca@interceptpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
